Vulvar Neoplasms clinical trials

The registry lists 236 studies for Vulvar Neoplasms across more than 10 countries. 69 are recruiting or about to start. 62 of them are mainly about Vulvar Neoplasms (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10.

Get an email when these change. Save the Vulvar Neoplasms studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 104
Recruiting: 53
Status unknown: 21
Active, not recruiting: 20
Terminated: 15
Not yet recruiting: 14

Phase

Phase 2: 56
Phase 1: 36
Phase 3: 23
Early Phase 1: 2
Phase 4: 1

Where

United States: 107
China: 21
United Kingdom: 16
Italy: 15
Canada: 11
France: 10

Who runs them

Merck Sharp & Dohme LLC (11) · Gynecologic Oncology Group (11) · M.D. Anderson Cancer Center (8) · National Cancer Institute (NCI) (8) · Ohio State University Comprehensive Cancer Center (6) · Dana-Farber Cancer Institute (5) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (5) · Shanghai Bovax Biotechnology Co., Ltd. (5)

What is being tested here

Drugs under test in Vulvar Neoplasms studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Pembrolizumab	2	0	6
Cisplatin	2	1	6
Therapeutic Tumor Infiltrating Lymphocytes	2	0	2
Lenvatinib	2	0	2
Human Papillomavirus Recombinant Vaccine nonavalent	1	6	6
Indocyanine Green	1	1	2
Dehydroepiandrosterone	1	1	2
Paclitaxel	1	0	2
Tisotumab vedotin	1	0	1
Cemiplimab	1	0	1

Drug classes tested here Immune checkpoint inhibitors 5 open · Tyrosine kinase inhibitors (TKIs) 3 open · Antimitotic agents 1 open · Angiogenesis inhibitors 4 · Antimetabolites 3

Coming up

4phase 3 studies under way

29studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Sep 2027Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females · Phase 3 · Shanghai Bovax Biotechnology Co., Ltd.
Nov 2026Charcoal Carbon Black Dye Use in Sentinel Lymph Node Mapping in Early Stage Vulvar Cancer · Istanbul University
Dec 2026Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma · SCG Cell Therapy Pte. Ltd.
Dec 2026Using Reiki Therapy to Improve Symptoms Associated With Brachytherapy in Patients With Gynecological Malignancies · University of Utah
Dec 2026Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types · University of Florida
Dec 2026Image-Guided Gynecologic Brachytherapy · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Dec 2026Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin · Dana-Farber Cancer Institute
Dec 2026Nelfinavir, Cisplatin, and External Beam Radiation Therapy for the Treatment of Locally Advanced Vulvar Cancer That Cannot Be Removed by Surgery · M.D. Anderson Cancer Center
Dec 2026Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers · Emory University
Dec 2026Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer · Ohio State University Comprehensive Cancer Center

Who these studies take

Of the 53 Vulvar Neoplasms studies recruiting now, 39 (74%) set no upper age limit and 7 (13%) stop at 75 or younger. 4 (8%) take children under 18. 33 (62%) are for women only and 0 (0%) for men only; 6 (11%) take healthy volunteers.

Recruiting studies that take each age, of 53
Age	Women	Men
10	4 (8%)	1 (2%)
18	50 (94%)	20 (38%)
30	51 (96%)	20 (38%)
40	52 (98%)	20 (38%)
50	51 (96%)	20 (38%)
65	50 (94%)	20 (38%)
75	49 (92%)	19 (36%)
85	43 (81%)	17 (32%)

Across all 236 studies, recruiting or not: 14% stop at 75 or younger and 11% at 65; 14% take children; 68% are for women only and 0% for men only; 16% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Vulvar Neoplasms studies take

Of 12 phase 3 interventional studies under Vulvar Neoplasms, half reached primary completion within 19 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 3	19 mo13–24 · 12 studies	—	—
Interventional, no phase	28 mo17–129 · 43 studies	—	28 mo17–129 · 43 studies
Observational	75 mo41–151 · 32 studies	—	—

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 13, 2026.

Newly registered2

Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological CancersOct 28, 2026NCT07902375
Radiotherapy for Gynecologic Cancer With Up to 10 Active Metastatic LesionsOct 20, 2026NCT07883798

Studies

Recruiting first, then most recently updated. Showing 50 of 236. Browse all 236 → or search them.